A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

Read more
"Relapsed Multiple Myeloma Treatment Preferences and Priorities for Patients and Caregivers in the US –A Sub-study of the CoMMpass Longitudinal Study "
“Relapsed Multiple Myeloma Treatment Preferences and Priorities for Patients and Caregivers in the US –A Sub-study of the CoMMpass Longitudinal Study “

“Relapsed Multiple Myeloma Treatment Preferences and Priorities for Patients and Caregivers in the US –A Sub-study of the CoMMpass Longitudinal Study “

Read more
Longterm Follow up of Subjects treated with bb2121
Longterm Follow up of Subjects treated with bb2121

Longterm Follow up of Subjects treated with bb2121

Read more
BMT CTN PROTOCOL 1302, Multicenter Phase II, Double Blind, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
BMT CTN PROTOCOL 1302, Multicenter Phase II, Double Blind, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

BMT CTN PROTOCOL 1302, Multicenter Phase II, Double Blind, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

Read more
A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies
A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies

A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies

Read more
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Read more
A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma
A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

A Phase 2, Multicenter Study of the Efficacy and Safety of bb2121 in Subjects with Relapsed / Refractory Multiple Myeloma

Read more
A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Read more
A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma
A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma

Read more
A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Read more